Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

661
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
661
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

477
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
477
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

401
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
401
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

1.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

437
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
437
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

315
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
315

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Safety and Tolerability of the 1440- and 1927-nm Non-Ablative Fractional Diode Laser System for Skin Resurfacing: A Review of Current Literature.

Journal of cosmetic dermatology·2025
Same author

Photodynamic Skincare: A Prospective Single-Center Study.

Journal of drugs in dermatology : JDD·2024
Same author

Novel Clinical Applications of Topical Ruxolitinib: A Case Series.

Journal of drugs in dermatology : JDD·2024
Same author

Painful Ulcerating Lesions on the Breast.

Cutis·2022
Same author

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis.

The Journal of investigative dermatology·2021
Same author

Alopecia Areata: A Complex Cytokine Driven Disease.

The journal of investigative dermatology. Symposium proceedings·2020

相关实验视频

Updated: Jun 15, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

22.9K

里姆巴托毒素B:一个更新

Teresa Song1,2, Ellen S Marmur1,2

  • 1Marmur Medical, New York, New York.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
|August 28, 2024
PubMed
概括

里马胺毒素B为治疗面部纹和水过多等疾病提供了安全有效的替代方案,特别是在对A型抗药性患者的治疗中. 常见的副作用包括口腔干燥和消化不良,与A型相比,作用的开始更快.

科学领域:

  • 神经学 神经学
  • 皮肤病学 皮肤病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 甲型玻尿酸毒素是一种广泛使用的医疗和美容治疗.
  • 玻尿酸B型毒素 (rimabotulinumtoxinB) 正在引起人们的兴趣,特别是在耐治疗病例中.

研究的目的:

  • 审查FDA批准的和新兴的临床用途的rimabotulinumtoxinB.
  • 评估其在各种适应症中的疗效和安全性.

主要方法:

  • 在PubMed数据库的文献综述.
  • 食品和药物管理局指导方针的分析.

主要成果:

  • 针对B型毒素的特定转换比率被观察到面部节律,宫 dystonia,超,和sialorrhea.
  • 乙型毒素在治疗面部节律,宫 dystonia,sialorrhea 和超症方面表现出有效性.

结论:

  • 里姆巴托毒素B在几种疾病中是安全有效的,具有潜在的新应用.
  • 口腔干燥和消化不良是最常见的副作用.
  • B型毒素表现出更快的发作和剂量依赖的效果和不良事件.

更多相关视频

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.0K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

8.6K

相关实验视频

Last Updated: Jun 15, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

22.9K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.0K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

8.6K